Video Experimental Relacionado

Updated: May 7, 2026

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

YRDC es un biomarcador relacionado con el pronóstico correlacionado con la infiltración inmune y la sensibilidad a

Li Qiao^1,2, Yuetong Zhang¹, Pin Huang^1,3

¹State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Cancer reports (Hoboken, N.J.)

|September 3, 2025

Resumen

YRDC se sobreexpresa en muchos cánceres, vinculado a un mal pronóstico, y afecta el crecimiento del tumor, la infiltración inmune y la resistencia a los medicamentos. Se muestra prometedor como biomarcador para la inmunoterapia y la eficacia del fármaco dirigido.

Área de la Ciencia:

En el campo de la oncología
Biología del cáncer
Descubrimiento de biomarcadores

Sus antecedentes:

El papel de YRDC como biomarcador del cáncer no se entiende bien.
Su valor pronóstico, los mecanismos oncogénicos y el impacto en la eficacia del fármaco en todos los tipos de cáncer requieren más investigación.

Objetivo del estudio:

Investigar exhaustivamente el papel de YRDC en el cáncer de páncreas.
Para explorar los efectos de YRDC en la infiltración inmune y la sensibilidad a los medicamentos contra el cáncer.

Principales métodos:

Análisis bioinformático de los datos multimodales.
Se han investigado la expresión YRDC, las alteraciones genéticas, las variaciones del número de copias y los niveles de metilación.

Principales resultados:

YRDC se sobreexpresa y se asocia con un peor pronóstico en varios tumores.
YRDC promueve la progresión del cáncer al mejorar la proliferación, modular la infiltración inmune y aumentar la resistencia a los medicamentos.
YRDC predice la respuesta de la inmunoterapia y la eficacia del fármaco dirigido.

Conclusiones:

YRDC es un nuevo objetivo terapéutico y biomarcador para la progresión del cáncer.
YRDC es un biomarcador prometedor para predecir la respuesta a la inmunoterapia y la sensibilidad al fármaco objetivo.
Los hallazgos apoyan la investigación y las aplicaciones clínicas de YRDC en el cáncer.

Palabras clave:

YRDC (en inglés)el biomarcador sensibilidad al fármaco inmunoterapia Cáncer de páncreas

Más Videos Relacionados

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Videos de Conceptos Relacionados

Cross-reactivity

Cross-reactivity

Drug-Receptor Interactions

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...